Skip to main content

Table 3 Univariable and multivariable analysis of risk factors for genotypic pyrazinamide resistance (pncA mutation)

From: Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China

CharacteristicAll cases
n (%)
Wild type in pncA gene
n (%)
Mutation in pncA gene
n (%)
Crude
Prevalence ratio (95%CI)
Adjusted
Prevalence ratio (95%CI)
P value
Gender
 Male211 (65.1)136 (66.7)75 (62.5)1.01.0 
 Female113 (34.9)68 (33.3)45 (37.5)1.12 (0.84–1.50)11 (0.82–1.46)0.56
Age (years)
 <40153 (47.2)87 (42.6)66 (55.0)1.01.0 
 40–59108 (33.3)69 (33.8)39 (32.5)0.84 (0.61–1.14)0.82 (0.60–1.11)0.20
6063 (19.4)48 (23.5)15 (12.5)0.55 (0.34–0.89)0.56 (0.34–0.91)0.02
Residence in area within China
 East of china104 (32.1)69 (33.8)35 (29.2)1.0NA 
 Central of china162 (50.0)96 (47.1)66 (55.0)1.21 (0.87–1.68)NA 
 West of china58 (17.9)39 (19.1)19 (15.8)0.97 (0.61–1.54)NA 
Occupationv
 Farmer202 (62.3)135 (66.2)67 (55.8)1.0NA 
 Others122 (37.7)69 (33.8)53 (44.2)1.31 (0.99–1.74)NA 
Residence in area according to start DOTS implementation
 In 2000 or later187 (57.7)112 (54.9)75 (62.5)1.0NA 
 Before 2000137 (42.3)92 (45.1)45 (37.5)0.82 (0.61–1.10)NA 
Number of previous treatments
 0132 (40.7)88 (43.1)44 (36.7)1.0  
 1107 (33.0)67 (32.8)40 (33.3)1.12 (0.80–1.58)1.17 (0.84–1.63)0.35
 More than 181 (25.0)47 (23.0)34 (28.3)1.26 (0.89–1.79)1.55 (0.90–1.84)0.18
 Unknown4 (1.2)2 (1.0)2 (1.7)1.50 (0.55–4.12)2.56 (1.72–3.82)< 0.001
Previous pyrazinamide usage
 Yes144 (44.4)93 (45.6)51 (42.5)1.0NA 
 No180 (55.6)111 (54.4)69 (57.5)1.08 (0.81–1.44)NA 
Genotype
 Non-beijing strain42 (13.0)32 (15.7)10 (8.3)1.01.0 
 Beijing strain230 (71.0)139 (68.1)91 (75.8)1.66 (0.95–2.92)1.84 (1.01–3.34)0.045
 No data52 (16.0)33 (16.2)19 (15.8)1.54 (0.80–2.94)1.64 (0.82–3.25)0.16
  1. Note: NA not applicable, these variables were not included in the final mode